tbuckley/cabot-search huggingface dataset:
A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 Trial
Authors: M. Werner-Wasik, S. Swann, W. Curran, F. Robert, R. Komaki, C. P. Lee, S. Jafar, R. Share, H. Choy, G. Blumenschein
Journal: Journal of Clinical Oncology (2005)

7135 Background: Cetuximab (C225) is a chimerized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). NSCLC commonly overexpresses the EGFR, which is associated with aggressive tumor behavior and poor clinical outcome. Preclinical model systems demonstrate radiosensitization following molecular inhibition of EGFR signaling. An ongoing Phase II trial is testing cetuximab, with CRT, in unresectable stage III NSCLC. Methods: Eligibility criteria include Zubrod performance status (PS) ≤1, weight loss ≤5% over past 3 months, FEV1≥1.2 l, adequate hematologic, hepatic, and renal function. PTS receive an initial dose of C225 (400 mg/m2) on day 1 of week 1, then weekly doses of C225 (250 mg/m2) until completion of therapy (weeks 2 - 17). Starting on week 2, patients receive CRT (63 Gy/35 fractions) with weekly carboplatin (C) AUC 2 and paclitaxel (P) 45 mg/m2 x 6 doses followed by C (AUC 6) and P (200 mg/m2) x 2 cycles (weeks 12–17). Interim monitoring for severe (grade ≥3) or excessive non-hematological toxicities will occur after PTS have been treated and followed for at least 90 days after RT. Endpoints include safety and compliance of concurrent C225 and CRT. Results: 34 PTS have been entered to date with toxicity data available on 8. PTS characteristics (n=22): 77% male, median age 63.5 years (range 44–84), 45% PS 0, 55% stage IIIA. Toxicity data (n=8): 1 PT with grade 3 thrombocytopenia and 1 PT with grade 4 granulocytopenia. Number of grade 3 non-hematological toxicities: fatigue (2), dyspnea (2), anorexia (1), cardiac (2), neurologic (1), pain (1), and cataract (1). Number of grade 4 non-hematologic toxicities: dyspnea (1). Conclusions: Patient accrual is ongoing. Updated toxicities will be reported. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb
Male Factor Teratogenesis
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ontogeny of hepatobiliary secretion: Role of glutathione
Authors: P Mohan
Journal: Hepatology (1994)

The ontogeny of hepatic synthesis and biliary secretion of glutathione was characterized and correlated with hepatic gamma glutamyl transpeptidase, bile flow rate, biliary bile acids and amino acids in Sprague-Dawley rats at 18 days of gestation and postnatally at ages 7, 14, 21, 28 and 54 days. Bile was collected by bile duct cannulation under intraperitoneal anesthesia with nembutal/ketamine. Glutathione, gamma glutamyl transpeptidase and bile acids were analyzed enzymatically and amino acids by high-performance liquid chromatography using established methods. Hepatic glutathione was low in the fetus, but increased to approximate adult levels by 7 days postnatally (2.77 μmol/gm liver). Hepatic gamma glutamyl transpeptidase activity, high in the fetus, declined to adult levels by day 7 (0.03 μmol/mg protein). In contrast, significant efflux of glutathione and its constituent amino acids into bile did not occur until weaning (21 days of age). During weaning, there was a fivefold increase in the biliary glutathione and with a twofold increase in bile flow rate. Biliary bile acids concentration remained constant throughout development, with only a 30% to 50% increase in its secretion rate. The data suggest that the developmentally related increase in bile flow rate was principally a result of the increase in bile acid independent flow from 1.1 μl/(min · 100 gm body wt) in the suckling to 4.3 μl/(min · 100 gm body wt) in the post-weanling animal. Conclusions: (1) bile formation in the suckling is largely dependent on bile acids secretion, in the absence of a significant bile acids independent component; (2) glutathione and amino acids play a major role in promoting bile acid independent flow; and (3) the development of mechanisms for biliary glutathione secretion succeeds those of hepatic glutathione synthesis and provides a potential model for investigating the ontogeny of canalicular transport processes and the role of glutathione in bile formation. (HEPATOLOGY 1994;19:1504–1512.)
Antifertility Effects and Dominant Lethal Assays for Mutagenic Effects of DEHP
Authors: John Autian
Journal: Environmental Health Perspectives (1982)

Results of past animal studies have indicated the antifertility effects of phthalate esters and additional studies have suggested the potential mutagenic effects at very high doses. A toxicity study in mice has also been conducted in which chronic LD50 values were calculated for a group of phthalate esters. For DEHP, for example, the acute LD50 was 38.35 ml/kg, but after 10 weeks the value fell to 1.37 ml/kg, suggesting that the ester was producing a cumulative toxicity agent even at lower doses in regard to antifertility and mutagenic effects in mice. Preliminary results indicated that antifertility effects occurred with as little as three subcutaneous doses of 1 ml/kg each. Calculations of mutagenic index revealed a dose-dependent effect but no stoichiometric relationship was established.
Fron the Alcohol, Drug Abuse and Mental Health Administration
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Roentgenography of Urinary Tract During Excretion of Sodium Iodid
Authors: Earl D. Osborne
Journal: JAMA (1983)

There is need of a simple and painless method of depicting the urinary tract, bladder, kidneys and ureters. By the use of catheters and various opaque mediums, success has been attained so far as the bladder, ureters and pelves of the kidney are concerned. Cystography and urography, while of great importance, are not without drawbacks and limitations. The use of the urethral or ureteral catheter is subject to obvious objections from both the physician's and the patient's standpoint. Technically, ureteral catheterization is at times very difficult, and it often subjects the patient to excruciating pain and occasionally to serious reactions. While pyelography may clearly delineate the renal pelves, it may fail to reveal the outline of the kidney itself. In surgical and medical diseases of the kidney, information concerning the size and location of these organs is of paramount interest. In nephritis, for example, it would be of decided value
Thyroid hormone and TGF-? inhibition drive functional maturation of human pluripotent stem cell-derived hepatocytes
Authors: Sarah Withey, Dave Gerrard, Hannah Leeson, Rebecca Atkinson-Dell, Sean Harrison, Melissa Baxter, Ali Al-Anbaki, Karen Piper Hanley, Ernst Wolvetang, Neil Hanley
Journal: Journal of Hepatology (2020)
“Do Everything”
Authors: Matthew Wynia
Journal: Annals of Internal Medicine (1994)

Letters1 July 1994“Do Everything”Matthew Wynia, MDMatthew Wynia, MDHarvard Medical School; Deaconess Hospital; Boston, MA 02215Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-1-199407010-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The man was 45 years old and dying of liver failure. In an encephalopathic coma and on three vasopressors to maintain a blood pressure of 70 mm Hg, he had progressive renal insufficiency despite hydration and required intubation. Several times his wife was asked whether he should have do-not-resuscitate (DNR) status. Each time she reflected, then tearfully said that the team should “do everything”—and so they did. I made rounds with his team in the intensive care unit one day, and as we discussed the hopelessness of his situation in conference his pressure dropped. The attending physician ... Author, Article, and Disclosure InformationAffiliations: Harvard Medical School; Deaconess Hospital; Boston, MA 02215 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1994Volume 121, Issue 1Page: 77KeywordsBlood pressureCardiopulmonary resuscitationComaDeceptionDo not resuscitate ordersIntensive care unitsIntubationLiverLiver transplantationVasopressors Issue Published: 1 July 1994 CopyrightCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Abstract 19364: C-Kit <sup>+</sup> Cardiac Progenitor Cells are Important in Cardiomyocytes Generation i <i>n vivo</i> in Response to Sfrp2
Authors: Jose Gomez, Conrad Hodgkinson, Alan Payne, Jeffrey Scmeckpeper, Lunan Zhang, Lan Mao, Victor Dzau
Journal: Circulation (2015)

Introduction: Resident c-Kit + cardiac progenitor cells (CPCs) differentiation into cardiomyocytes in vivo is controversial. Using lineage tracing and gene ablation techniques we documented that the Wnt signaling modulator Sfrp2 substantially increased differentiation of c-Kit + CPCs into cardiomyocytes in post-MI heart and restored cardiac function. Methods: c-Kit-CreERT2/mTeG mice were used where the c-Kit promoter drives expression of a tamoxifen (TX)-inducible Cre. Upon TX treatment Cre-mediated recombination drives expression of eGFP exclusively in c-Kit cells. Mice were crossed with a Diphtheria toxin receptor (DT) strain to selectively ablate heart c-Kit cells. Mice were subjected to myocardial infarction. 2 days later, mice were injected with Sfrp2 (0.5 μg) or saline at the infarct border zone. Heart tissue was analyzed 2 months post-MI for eGFP expression and various markers by microscopy. Results: c-Kit-CreERT2/mTeG model was tested. eGFP expression had no effect on in vitro c-Kit CPC differentiation or proliferation. In TX treated mice, &gt;90% of c-Kit+ cells were eGFP+. No eGFP+ c-Kit+ cells were seen in vehicle-only mice (N=6, p&lt;0.001). c-Kit negative cells, such as cardiomyocytes, endothelial cells, and smooth muscle cells, did not express eGFP following TX treatment. In sham animals, eGFP was localized to small c-Kit+ cells. In the vehicle MI group eGFP+ cardiomyocytes were rare (0.08% in infarct border zone. N=8, P=0.005). In contrast, the number of eGFP+ cardiomyocytes was significantly higher in the Sfrp2 treated group (15% in infarct border zone, N=10, P=0.0002). Co-localization of eGFP with blood vessels (0.77%, N=10) was infrequent. Induction of c-Kit CPC differentiation into cardiomyocytes by Sfrp2 was associated with lower fibrosis (15%, N=10, P=0.01), higher LV mass (58mg, N=10, P=0.01) and increased ejection fraction (16%, N=10, P=0.02). DT treatment ablated c-Kit cells (&gt;95% N=4, P=0.01). Sfrp2 induction of c-Kit differentiation to cardiomyocytes and functional improvements were completely ablated by DT. Conclusion: Using c-Kit lineage-tracing and genetic ablation we have identified that these cells are important in cardiomyocyte generation in vivo in response to Sfrp2 and improves cardiac function following MI.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1961)

COMMITTEE ON MATERNAL WELFARE*Sepsis Resulting in AutolysisAt about 1 a.m. a thirty-year-old gravida 5, para 3, weighing 92 kg. (203 pounds) was admitted to the hospital in early labor at term having made only one prenatal visit. She was medicated promptly, and although the membranes ruptured spontaneously at 5 a.m. labor subsided and she was allowed to wake up. The vertex was out of reach. At noon the fluid became bloody but there were no contractions, and with the presenting part still floating the patient was discharged at about 9 p.m. at her own insistence despite notoriously inferior . . .
ADAMKIEWICZ ON THE NATURE AND TREATMENT OF CANCER.
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Economic Analysis of Influenza Vaccination and Treatment
Authors: Afschin Gandjour
Journal: Annals of Internal Medicine (2003)

Letters1 April 2003Economic Analysis of Influenza Vaccination and TreatmentAfschin Gandjour, MD, PhDAfschin Gandjour, MD, PhDUniversity of Cologne; 50935 Kln, Germany (Gandjour)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-7-200304010-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Lee and colleagues present a cost–benefit analysis on influenza vaccination and treatment for healthy working adults from a societal perspective (1). To determine the monetary benefit of vaccination and treatment, they asked primary care patients about their willingness to pay for a personal benefit. Although this approach is quite common (2), it has two problems.First, from a societal viewpoint, primary care patients may not be the right persons to ask. The authoritative guidelines of the U.S. Panel on Cost-Effectiveness in Health and Medicine (3) recommend eliciting the preferences of the community or general population, not those ...References1. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med. 2002;137:225-31. [PMID: 12186512] LinkGoogle Scholar2. Olsen JA, Smith RD. Theory versus practice: a review of willingness-to-pay in health and health care. Health Econ. 2001;10:39-52. [PMID: 11180568] CrossrefMedlineGoogle Scholar3. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7. [PMID: 8827972] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Cologne; 50935 Kln, Germany (Gandjour) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEconomic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults Patrick Y. Lee , David B. Matchar , Dennis A. Clements , Joel Huber , John D. Hamilton , and Eric D. Peterson Economic Analysis of Influenza Vaccination and Treatment Martin I. Meltzer and Carolyn B. Bridges Economic Analysis of Influenza Vaccination and Treatment Patrick Y. Lee and Eric D. Peterson Economic Analysis of Influenza Vaccination and Treatment Tom Jefferson and Vittorio Demicheli Economic Analysis of Influenza Vaccination and Treatment Henry Brodkin Metrics 1 April 2003Volume 138, Issue 7Page: 607-608KeywordsHealth economicsPatient advocacyPatientsTaxes ePublished: 1 April 2003 Issue Published: 1 April 2003 CopyrightCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Psychiatry
Authors: Peter M. Marzuk
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer Risk of Pesticides in Agricultural Workers
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.
Authors: Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba, Thomas E Boyd, Robert N Raju, David N Barrera, Ernest Cochran, Philip Dien, David Hakimian, Roger M. Lyons, Peter J Schlegel, Svetislava J Vukelja, Julie Boston, Kristi A Boehm, Yunfei Wang, Lina Asmar
Journal: Blood (2008)
Reply to M.C. Chamberlain
Authors: Roger Stupp, Monika E. Hegi, Bart Neyns, Roland Goldbrunner, Uwe Schlegel, Paul M.J. Clement, Gerhard G. Grabenbauer, Adrian F. Ochsenbein, Matthias Simon, Pierre-Yves Dietrich, Torsten Pietsch, Christine B. Hicking, Joerg-Christian Tonn, Annie-Claire Diserens, Alessia Pica, Mirjam Hermisson, Martin Picard, Michael Weller
Journal: Journal of Clinical Oncology (2010)
After Aleppo
Authors: Jennifer Franklin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening for non-alcoholic fatty liver disease in persons with type 2 diabetes in the U.S. is cost effective: A comprehensive economical analysis
Authors: Mazen Noureddin, Calum Jones, Msc, Eduardo Vilar Gomez, Naim Alkhouri, George Therapondos, Parvez Mantry, Nigel Girgrah, Eric Mitchell, Kristen Shea, Mph, Norman L. Sussman, Michael Fuchs, Dr. Viviana Figueroa Diaz, Amreen Dinani, Douglas Dieterich, Mary Rinella
Journal: Journal of Hepatology (2020)